Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

CRISPR Therapeutics AG - Common Shares (NQ:CRSP)

41.64 -0.22 (-0.53%)
Streaming Delayed Price Updated: 1:46 PM EDT, Jun 9, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about CRISPR Therapeutics AG - Common Shares

< Previous 1 2
...
21 22 23 24 25 26 27 28 29
...
32 33 Next >
2 Growth Stocks That Could Help Set You Up for Life
Many growth stocks are down, but they're not all out. 
Via The Motley Fool
5 Best Bargain Stocks to Buy Before 2023
It's time to hit the best sale in town, and that involves many top stocks. 
Via The Motley Fool
3 Revolutionary Stocks I'd Buy Right Now Without Hesitation
The three companies are changing the pharmaceutical industry. 
Via The Motley Fool
Is CRISPR Therapeutics a Buy?
A strong cash position could offset some of the near-term risks that come with owning the biotech. 
Via The Motley Fool
Precigen's Overnight Cell Manufacturing Technology Could Offer Advanced AML Patients The Option Of Promising CAR-T Therapy
-Clinical Data Due Next Week at ASH- 
Via Benzinga
What 5 Analyst Ratings Have To Say About CRISPR Therapeutics
Via Benzinga
Why Shares of CRISPR Therapeutics Dropped 19.9% in October
Several factors weighed on the gene-editing biotech stocks last month. 
Via The Motley Fool
Where CRISPR Therapeutics Stands With Analysts
CRISPR Therapeutics (NASDAQ:CRSP) has observed the following analyst ratings within the last quarter: 
Via Benzinga
2 Unstoppable Growth Stocks to Buy in 2022 and Beyond
These biotech players beat the bear market this year. 
Via The Motley Fool
3 Fierce Stocks That Are Screaming Buys in December
Here are three winners in the making. 
Via The Motley Fool
Is It Too Late to Buy Vertex Pharmaceuticals Stock?
The company has already made plenty of investors happy. 
Via The Motley Fool
Bear Market Bargain Hunting: 3 Top Stocks to Buy Before 2023
These top players are ripe for recovery -- and long-term growth. 
Via The Motley Fool
3 Growth Stocks That Are Too Cheap to Ignore
Overlooking these stocks in the current market could be a mistake. 
Via The Motley Fool
Cathie Wood Has Bet Big On These 10 Stocks; Here's How They're Performing
Here's how Ark Invest's top holdings have performed in 2022. 
Via Investor's Business Daily
2 Stocks Near 52-Week Highs That Could Climb Higher
This pair of stocks are bucking the trend and they could climb even higher. 
Via The Motley Fool
Cathie Wood Is Selling This High-Flying Stock. Here's Why You Should Buy It Instead
The ARK Invest founder might regret trimming her position in this biotech stock. 
Via The Motley Fool
How to Trade the High-Growth Biotech Sector in the Midst of a Bear Market
Biotech is an exciting and emerging space that’s attracted increasing investor interest in recent years. 
Via Benzinga
Where Will Editas Medicine Be in 1 Year?
The company could continue lagging the market for a while. 
Via The Motley Fool
2 Growth Stocks That Could Double in 2023
Both are lagging the market this year. 
Via The Motley Fool
Crispr Therapeutics Stock: Bull vs. Bear
Crispr shares have fallen about 20% so far this year. 
Via The Motley Fool
5 Top Stocks to Buy Before 2023
These stocks have what it takes to win over time. 
Via The Motley Fool
Vertex Pharmaceuticals: Buy at the High?
Vertex is submitting a potential blockbuster to regulators this month. 
Via The Motley Fool
Want $1 Million in Retirement? Invest $100,000 in These 3 Stocks and Wait a Decade
These top stocks could be wise additions to a well-rounded investment portfolio. 
Via The Motley Fool
3 Top Healthcare Stocks Defying the Bear Market
These healthcare companies haven't been slowed by macroeconomic conditions. 
Via The Motley Fool
$100 Invested In This Stock 5 Years Ago Would Be Worth $300 Today
CRISPR Therapeutics (NASDAQ:CRSP) has outperformed the market over the past 5 years by 15.41% on an annualized basis producing an average annual return of 23.37%. Currently, CRISPR Therapeutics has a... 
Via Benzinga
3 Healthcare Stocks That Could Go Parabolic
These beaten-down stocks are ready for a rebound. 
Via The Motley Fool
Got $1,000? 2 Smart Stocks to Consider Buying Right Now
Don't overlook these major healthcare names on your next stock-buying spree. 
Via The Motley Fool
2 Biotech Stocks That Could Make You Richer
Both drugmakers are pretty close to their 52-week highs, but that shouldn't stop investors. 
Via The Motley Fool
3 Top Healthcare Stocks to Buy for November
Catalysts lie ahead for these promising stocks. 
Via The Motley Fool
What 8 Analyst Ratings Have To Say About CRISPR Therapeutics
Within the last quarter, CRISPR Therapeutics (NASDAQ:CRSP) has observed the following analyst ratings: 
Via Benzinga
< Previous 1 2
...
21 22 23 24 25 26 27 28 29
...
32 33 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.